China Medical System Holdings (HK:0867) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Medical System Holdings has secured exclusive rights to commercialize ABP-671, a promising Class 1 innovative drug for treating gout and hyperuricemia, in Mainland China, Hong Kong, and Macao. The drug, currently in advanced clinical trials, demonstrates superior efficacy and safety compared to existing treatments, potentially addressing a significant market need as these conditions are on the rise in China.
For further insights into HK:0867 stock, check out TipRanks’ Stock Analysis page.